Literature DB >> 29119048

Elucidating immunometabolic targets in glioblastoma.

Pooja Agarwal1, Michael J Pajor1, David M Anson1, Maheedhara R Guda1, Collin M Labak1, Andrew J Tsung1,2,3, Kiran K Velpula1,2.   

Abstract

Immunometabolism has recently emerged on the forefront of cancer research as a new avenue to potentially develop more effective and targeted treatment options. Several pathologically altered metabolic targets across various cancer types have been identified, including lactate in aerobic glycolysis; tryptophan in amino acid metabolism; and arginine in the urea cycle. Numerous advancements have improved our understanding of the dual function of these targets in influencing immune functions as an auxiliary function to their well-established metabolic role. This paper provides a comprehensive overview of immunometabolism research and attempts to provide insight into potential immunometabolic targets in glioblastoma for the purpose of future development and study of targeted therapies.

Entities:  

Keywords:  Arg1; IDO; Immunometabolism; LDHA; TDO; arginine; glioblastoma; iNOS; lactate; lactic acid; tryptophan

Year:  2017        PMID: 29119048      PMCID: PMC5665846     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  31 in total

1.  Fatal attraction: tumors beckon regulatory T cells.

Authors:  Ethan M Shevach
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

2.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

3.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

4.  Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.

Authors:  Kiran Kumar Velpula; Arnima Bhasin; Swapna Asuthkar; Andrew J Tsung
Journal:  Cancer Res       Date:  2013-10-22       Impact factor: 12.701

5.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

Review 6.  Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages.

Authors:  Meera Rath; Ingrid Müller; Pascale Kropf; Ellen I Closs; Markus Munder
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

7.  The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Calogero Vetro; Daniele Tibullo; Cesarina Giallongo; Piera La Cava; Annalisa Chiarenza; Giovanna Motta; Anastasia L Caruso; Loredana Villari; Claudio Tripodo; Sebastiano Cosentino; Massimo Ippolito; Ugo Consoli; Andrea Gallamini; Stefano Pileri; Francesco Di Raimondo
Journal:  Oncotarget       Date:  2016-10-11

Review 8.  Is cancer a disease of abnormal cellular metabolism? New angles on an old idea.

Authors:  Ralph J DeBerardinis
Journal:  Genet Med       Date:  2008-11       Impact factor: 8.822

9.  Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death.

Authors:  Simona Daniele; Chiara Giacomelli; Elisa Zappelli; Carlotta Granchi; Maria Letizia Trincavelli; Filippo Minutolo; Claudia Martini
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

10.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.

Authors:  Roger Geiger; Jan C Rieckmann; Tobias Wolf; Camilla Basso; Yuehan Feng; Tobias Fuhrer; Maria Kogadeeva; Paola Picotti; Felix Meissner; Matthias Mann; Nicola Zamboni; Federica Sallusto; Antonio Lanzavecchia
Journal:  Cell       Date:  2016-10-13       Impact factor: 41.582

View more
  3 in total

Review 1.  The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.

Authors:  Abhishek Guha; Saboora Waris; Louis B Nabors; Natalia Filippova; Myriam Gorospe; Thaddaeus Kwan; Peter H King
Journal:  Adv Drug Deliv Rev       Date:  2021-12-16       Impact factor: 15.470

Review 2.  Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?

Authors:  Lidia Gatto; Vincenzo Di Nunno; Enrico Franceschi; Alicia Tosoni; Stefania Bartolini; Alba Ariela Brandes
Journal:  Drugs       Date:  2022-04-09       Impact factor: 9.546

Review 3.  Metabolic Drivers of Invasion in Glioblastoma.

Authors:  Joseph H Garcia; Saket Jain; Manish K Aghi
Journal:  Front Cell Dev Biol       Date:  2021-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.